{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:59:44Z","timestamp":1788886784855,"version":"build-2803163510"},"reference-count":52,"publisher":"American Association for Cancer Research (AACR)","issue":"1","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-18-1-0547"],"award-info":[{"award-number":["W81XWH-18-1-0547"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015612","name":"CancerFree KIDS","doi-asserted-by":"publisher","award":["810455"],"award-info":[{"award-number":["810455"]}],"id":[{"id":"10.13039\/100015612","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Galloway and Franklin Families","award":["030-9308-996"],"award-info":[{"award-number":["030-9308-996"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>We previously generated an orthotopic, NF2-deficient meningioma model using the luciferase-expressing Ben-Men-1 cell line established from a sporadic tumor and identified the multikinase inhibitor brigatinib and the mTOR kinase inhibitor INK128 to potently impede tumor growth. In this study, we describe generation of the telomerase-immortalized AG-NF2-Men cell line from a grade-1 meningioma of a patient with NF2-related schwannomatosis (NF2-SWN). We showed that like Ben-Men-1 cells, AG-NF2-Men cells were NF2-null, expressed several NF2-regulated receptor tyrosine kinases, and responded to their cognate ligands. We also found that brigatinib and INK128 alone inhibited AG-NF2-Men cell proliferation at IC50 values similar to those in Ben-Men-1 cells. Combining brigatinib with INK128 exhibited growth-inhibitory synergy. Mechanistically, the combination not only completely abrogated p-AKT(S473) and its downstream signaling compared with either drug alone but also prevented INK128-mediated rephosphorylation of AKT on T308. Also, the combination more effectively blocked ligand-mediated phosphorylation of EGFR, ErbB3, and IGF-1R and elicited major changes in the expression of genes, including the upstream regulators of several signaling networks important for meningioma growth. Furthermore, we generated luciferase-expressing AG-NF2-Men cells that readily grew as intracranial xenografts. Importantly, combining brigatinib with INK128 enhanced tumor regression in both the orthotopic AG-NF2-Men and Ben-Men-1 xenograft models. As the first NF2-SWN\u2013related meningioma cell line, AG-NF2-Men is a unique reagent for investigating meningioma biology and therapeutics. A clinical trial to evaluate the combination of brigatinib with an mTOR inhibitor in NF2-deficient meningiomas is warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>AG-NF2-Men represents the first NF2-SWN\u2013related meningioma model. The brigatinib + INK128 combination exhibits antitumor synergy in both the AG-NF2-Men and Ben-Men-1 meningioma models, suggesting combining brigatinib with mTOR inhibition to more effectively treat NF2-SWN and sporadic NF2-deficient meningiomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0563","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:41:14Z","timestamp":1766169674000},"page":"211-223","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN\u2013Associated and Sporadic\n                    <i>NF2<\/i>\n                    -Deficient Meningiomas"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-2992","authenticated-orcid":false,"given":"Long-Sheng","family":"Chang","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/003rfsp33","id-type":"ROR","asserted-by":"publisher"}],"name":"Abigail Wexner Research Institute at Nationwide Children\u2019s Hospital 1 Center for Childhood Cancer, , Columbus, Ohio."},{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University College of Medicine 2 Department of Pediatrics, , Columbus, Ohio."},{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University College of Medicine 3 Department of Otolaryngology-Head & Neck Surgery, , Columbus, Ohio."},{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University College of Medicine 4 Department of Pathology, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6044-5624","authenticated-orcid":false,"given":"Janet L.","family":"Oblinger","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/003rfsp33","id-type":"ROR","asserted-by":"publisher"}],"name":"Abigail Wexner Research Institute at Nationwide Children\u2019s Hospital 1 Center for Childhood Cancer, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7285-3606","authenticated-orcid":false,"given":"Lai Man Natalie","family":"Wu","sequence":"additional","affiliation":[{"name":"5Division of Experimental Hematology and Cancer Biology, Brain Tumor Center, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6110-6069","authenticated-orcid":false,"given":"Cecelia","family":"Miller","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University College of Medicine 4 Department of Pathology, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6907-2366","authenticated-orcid":false,"given":"Sarah S.","family":"Burns","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/003rfsp33","id-type":"ROR","asserted-by":"publisher"}],"name":"Abigail Wexner Research Institute at Nationwide Children\u2019s Hospital 1 Center for Childhood Cancer, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"Suppl 5","key":"2026012700240780300_bib1","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026012700240780300_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-010-0386-3","article-title":"Epidemiology and etiology of meningioma","volume":"99","author":"Wiemels","year":"2010","journal-title":"J Neurooncol"},{"key":"2026012700240780300_bib3","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/neuonc\/nos013","article-title":"Impaired survival and long-term neurological problems in benign meningioma","volume":"14","author":"van Alkemade","year":"2012","journal-title":"Neuro Oncol"},{"key":"2026012700240780300_bib4","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.gim.2022.05.007","article-title":"Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation","volume":"24","author":"Plotkin","year":"2022","journal-title":"Genet Med"},{"key":"2026012700240780300_bib5","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1158\/1078-0432.CCR-08-3011","article-title":"Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2","volume":"15","author":"Evans","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026012700240780300_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ajmg.a.34359","article-title":"Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2","volume":"158A","author":"Blakeley","year":"2012","journal-title":"Am J Med Genet A"},{"key":"2026012700240780300_bib7","first-page":"253","article-title":"Chapter 16. Meningiomas in children","volume-title":"Handbook of clinical neurology, Meningiomas, Part I","author":"Phillips","year":"2020"},{"key":"2026012700240780300_bib8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/363515a0","article-title":"Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2","volume":"363","author":"Rouleau","year":"1993","journal-title":"Nature"},{"key":"2026012700240780300_bib9","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-G","article-title":"A novel moesin-ezrin-radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor","volume":"72","author":"Trofatter","year":"1993","journal-title":"Cell"},{"key":"2026012700240780300_bib10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tcb.2009.02.006","article-title":"Merlin and the ERM proteins\u2013regulators of receptor distribution and signaling at the cell cortex","volume":"19","author":"McClatchey","year":"2009","journal-title":"Trends Cell Biol"},{"key":"2026012700240780300_bib11","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1101\/gad.1054603","article-title":"NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions","volume":"17","author":"Lallemand","year":"2003","journal-title":"Genes Dev"},{"key":"2026012700240780300_bib12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1083\/jcb.200703010","article-title":"Contact-dependent inhibition of EGFR signaling by Nf2\/Merlin","volume":"177","author":"Curto","year":"2007","journal-title":"J Cell Biol"},{"key":"2026012700240780300_bib13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/onc.2008.427","article-title":"Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas","volume":"28","author":"Lallemand","year":"2009","journal-title":"Oncogene"},{"key":"2026012700240780300_bib14","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","article-title":"Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK","volume":"25","author":"Poulikakos","year":"2006","journal-title":"Oncogene"},{"key":"2026012700240780300_bib15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"key":"2026012700240780300_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1534-5807(01)00009-0","article-title":"The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling","volume":"1","author":"Shaw","year":"2001","journal-title":"Dev Cell"},{"key":"2026012700240780300_bib17","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1158\/0008-5472.CAN-12-1888","article-title":"Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth","volume":"73","author":"Burns","year":"2013","journal-title":"Cancer Res"},{"key":"2026012700240780300_bib18","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/labinvest.3700307","article-title":"Establishment of a benign meningioma cell line by hTERT-mediated immortalization","volume":"85","author":"P\u00fcttmann","year":"2005","journal-title":"Lab Invest"},{"key":"2026012700240780300_bib19","doi-asserted-by":"crossref","first-page":"e0197350","DOI":"10.1371\/journal.pone.0197350","article-title":"Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2","volume":"13","author":"Allaway","year":"2018","journal-title":"PLoS One"},{"key":"2026012700240780300_bib20","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/neuonc\/noy046","article-title":"EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma","volume":"20","author":"Angus","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026012700240780300_bib21","doi-asserted-by":"crossref","first-page":"e0252048","DOI":"10.1371\/journal.pone.0252048","article-title":"Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK","volume":"16","author":"Chang","year":"2021","journal-title":"PLoS One"},{"key":"2026012700240780300_bib22","doi-asserted-by":"crossref","first-page":"29011","DOI":"10.18632\/oncotarget.8508","article-title":"Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice","volume":"7","author":"Siaw","year":"2016","journal-title":"Oncotarget"},{"key":"2026012700240780300_bib23","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa2400985","article-title":"Brigatinib in NF2-related schwannomatosis with progressive tumors","volume":"390","author":"Plotkin","year":"2024","journal-title":"N Engl J Med"},{"key":"2026012700240780300_bib24","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/neuonc\/noae137","article-title":"Expanding therapeutic options for people with NF2-related schwannomatosis: encouraging results with brigatinib","volume":"26","author":"Plotkin","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026012700240780300_bib25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-1-4939-3615-1_4","article-title":"Generation of noninvasive, quantifiable, orthotopic animal models for NF2-associated schwannoma and meningioma","volume":"1427","author":"Burns","year":"2016","journal-title":"Methods Mol Biol"},{"key":"2026012700240780300_bib26","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"2026012700240780300_bib27","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1002\/1097-0142(19891201)64:11<2243::AID-CNCR2820641110>3.0.CO;2-S","article-title":"Establishment of a human malignant meningioma cell line with amplified c-myc oncogene","volume":"64","author":"Tanaka","year":"1989","journal-title":"Cancer"},{"key":"2026012700240780300_bib28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1750-3639.2003.tb00034.x","article-title":"Pathological adhesion of primary human schwannoma cells is dependent on altered expression of integrins","volume":"13","author":"Utermark","year":"2003","journal-title":"Brain Pathol"},{"key":"2026012700240780300_bib29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.nbd.2007.09.002","article-title":"Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth","volume":"29","author":"James","year":"2008","journal-title":"Neurobiol Dis"},{"key":"2026012700240780300_bib30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00401-003-0736-8","article-title":"Molecular characterization of desmosomes in meningiomas and arachnoidal tissue","volume":"106","author":"Akat","year":"2003","journal-title":"Acta Neuropathol"},{"key":"2026012700240780300_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11060-005-9076-y","article-title":"A genetic strategy to overcome the senescence of primary meningioma cell cultures","volume":"78","author":"Baia","year":"2006","journal-title":"J Neurooncol"},{"key":"2026012700240780300_bib32","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1128\/MCB.01581-08","article-title":"NF2\/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth","volume":"29","author":"James","year":"2009","journal-title":"Mol Cell Biol"},{"key":"2026012700240780300_bib33","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1158\/1541-7786.MCR-11-0425-T","article-title":"Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types","volume":"10","author":"James","year":"2012","journal-title":"Mol Cancer Res"},{"key":"2026012700240780300_bib34","first-page":"vdae024","article-title":"Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in NF2-deficient models","volume":"6","author":"Bhattacharyya","year":"2024","journal-title":"Neurooncol Adv"},{"key":"2026012700240780300_bib35","doi-asserted-by":"crossref","first-page":"20750","DOI":"10.1074\/jbc.M011068200","article-title":"A quantitative molecular model for modulation of mammalian translation by the eIF4E-binding protein 1","volume":"276","author":"Karim","year":"2001","journal-title":"J Biol Chem"},{"key":"2026012700240780300_bib36","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1101\/gad.226302","article-title":"Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse","volume":"16","author":"Kalamarides","year":"2002","journal-title":"Genes Dev"},{"key":"2026012700240780300_bib37","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1038\/onc.2010.609","article-title":"Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes","volume":"30","author":"Kalamarides","year":"2011","journal-title":"Oncogene"},{"key":"2026012700240780300_bib38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/B978-0-12-804280-9.00008-1","article-title":"Preclinical models of meningioma: cell culture and animal systems","volume":"169","author":"Choudhury","year":"2020","journal-title":"Handb Clin Neurol"},{"key":"2026012700240780300_bib39","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1186\/s12967-023-04620-7","article-title":"Meningioma animal models: a systematic review and meta-analysis","volume":"21","author":"Andersen","year":"2023","journal-title":"J Transl Med"},{"key":"2026012700240780300_bib40","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.18632\/oncotarget.2810","article-title":"Group I Paks as therapeutic targets in NF2-deficient meningioma","volume":"6","author":"Chow","year":"2015","journal-title":"Oncotarget"},{"key":"2026012700240780300_bib41","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00401-021-02351-x","article-title":"Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas","volume":"142","author":"Kirches","year":"2021","journal-title":"Acta Neuropathol"},{"key":"2026012700240780300_bib42","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/ijms20010120","article-title":"Therapeutic inhibition of Myc in cancer. Structural bases and computer-aided drug discovery approaches","volume":"20","author":"Carabet","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2026012700240780300_bib43","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/neuonc\/not242","article-title":"mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma","volume":"16","author":"Giovannini","year":"2014","journal-title":"Neuro Oncol"},{"key":"2026012700240780300_bib44","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11060-017-2447-3","article-title":"A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas","volume":"133","author":"Goutagny","year":"2017","journal-title":"J Neurooncol"},{"key":"2026012700240780300_bib45","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/neuonc\/not150","article-title":"Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro Oncol"},{"key":"2026012700240780300_bib46","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1158\/1535-7163.MCT-21-0143","article-title":"Phase 0 clinical Trial of everolimus in patients with vestibular schwannoma or meningioma","volume":"20","author":"Karajannis","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2026012700240780300_bib47","first-page":"vdad041","article-title":"Prospective phase II trial of the dual mTORC1\/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2","volume":"5","author":"Jordan","year":"2023","journal-title":"Neurooncol Adv"},{"key":"2026012700240780300_bib48","doi-asserted-by":"crossref","first-page":"e2400327","DOI":"10.1200\/PO.24.00327","article-title":"Phase II study of defactinib (VS6063) in patients with tumors with NF2 loss: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol U","volume":"8","author":"Zauderer","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"2026012700240780300_bib49","doi-asserted-by":"crossref","first-page":"100157","DOI":"10.1074\/jbc.RA120.014960","article-title":"mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition","volume":"296","author":"Beauchamp","year":"2021","journal-title":"J Biol Chem"},{"key":"2026012700240780300_bib50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1021\/acs.jmedchem.2c01658","article-title":"Discovery of RMC-5552, a selective bi-steric inhibitor of mTORC1, for the treatment of mTORC1-activated tumors","volume":"66","author":"Burnett","year":"2023","journal-title":"J Med Chem"},{"key":"2026012700240780300_bib51","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","article-title":"mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling","volume":"1","author":"Rodrik-Outmezguine","year":"2011","journal-title":"Cancer Discov"},{"key":"2026012700240780300_bib52","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1593\/neo.08642","article-title":"The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP","volume":"10","author":"Striedinger","year":"2008","journal-title":"Neoplasia"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0563\/3717464\/crc-25-0563.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/1\/211\/3729647\/crc-25-0563.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/1\/211\/3729647\/crc-25-0563.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:24:22Z","timestamp":1769491462000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/1\/211\/771980\/Combining-Brigatinib-with-mTOR-Inhibition-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0563","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.31154436","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154424","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154412","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154400","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154379","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154418","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154406","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154373","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154442","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154385","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154430","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154397","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154403","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154433","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154439","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154427","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154415","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154394","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154382","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154421","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154388","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154391","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31154409","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8262945","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}